NASDAQ:ACTU Actuate Therapeutics 7/23/2024 Earnings Report $10.35 +0.45 (+4.55%) As of 05/9/2025 03:59 PM Eastern Earnings HistoryForecast Actuate Therapeutics EPS ResultsActual EPS-$5.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AActuate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AActuate Therapeutics Announcement DetailsQuarterDate7/23/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Actuate Therapeutics Earnings HeadlinesBlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice PresidentMay 9 at 8:44 AM | finance.yahoo.comActuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic CancerMay 8 at 5:45 PM | nasdaq.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 11, 2025 | Brownstone Research (Ad)Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic CancerMay 8 at 5:45 PM | seekingalpha.comActuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 ...May 6, 2025 | gurufocus.comActuate Therapeutics Announces Positive Phase 2 Trial ResultsMay 6, 2025 | tipranks.comSee More Actuate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email. Email Address About Actuate TherapeuticsActuate Therapeutics (NASDAQ:ACTU), Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.View Actuate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?DexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDisney Stock Jumps on Earnings—Is the Magic Sustainable? Upcoming Earnings Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)Sony Group (5/13/2025)SEA (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Copart (5/15/2025)NetEase (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
